Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bjørge

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 19, 1999
[The complement system--structure, activation, regulation and function]L Bjørge
Scandinavian Journal of Immunology|November 1, 1995
Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisoleL Bjørge, R Matre
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|October 9, 1998
How might pregnancy immunize against breast cancer?L Bjørge, R Matre
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|February 6, 2002
[Mifepristone--a controversial drug with great potential]L Bjørge, O E Iversen
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 14, 2000
[Pathophysiology and clinical manifestations in pre-eclampsia]K Haram, L Bjørge, K Guttu
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 14, 2000
[HELLP syndrome]K Haram, L Bjørge, K Guttu
Cancer Immunology, Immunotherapy : CII|March 1, 1996
Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell lineL Bjørge, T S Jensen, R Matre
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 14, 2000
[Pre-eclampsia--a review]K Haram, L Bjørge, K Guttu, et al.
European Journal of Immunology|July 1, 1994
Expression and function of CD59 on colonic adenocarcinoma cellsL Bjørge, C A Vedeler, E Ulvestad, et al.
Scandinavian Journal of Immunology|April 28, 2006
Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapyL Bjørge, H Stoiber, M P Dierich, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 19, 1999
[The complement system--structure, activation, regulation and function]L Bjørge
Scandinavian Journal of Immunology|November 1, 1995
Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisoleL Bjørge, R Matre
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|October 9, 1998
How might pregnancy immunize against breast cancer?L Bjørge, R Matre
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|February 6, 2002
[Mifepristone--a controversial drug with great potential]L Bjørge, O E Iversen
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 14, 2000
[Pathophysiology and clinical manifestations in pre-eclampsia]K Haram, L Bjørge, K Guttu
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 14, 2000
[HELLP syndrome]K Haram, L Bjørge, K Guttu
Cancer Immunology, Immunotherapy : CII|March 1, 1996
Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell lineL Bjørge, T S Jensen, R Matre
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 14, 2000
[Pre-eclampsia--a review]K Haram, L Bjørge, K Guttu, et al.
European Journal of Immunology|July 1, 1994
Expression and function of CD59 on colonic adenocarcinoma cellsL Bjørge, C A Vedeler, E Ulvestad, et al.
Scandinavian Journal of Immunology|April 28, 2006
Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapyL Bjørge, H Stoiber, M P Dierich, et al.
Pageof 4